Abbott Followed FDA Rules On Humira Updates, Jury Hears
At an Illinois trial over claims that AbbVie Inc. and Abbott Laboratories failed to adequately warn about blockbuster arthritis drug Humira's risks, a regulatory expert testified Friday that Abbott had acted...To view the full article, register now.
Already a subscriber? Click here to view full article